Apomorphine and sildenafil composition
US6087362A · kind A · utility
48Cited by
2References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 16, 1999 |
| Grant date | Jul 11, 2000 |
| Priority date | — |
| Expiry date | Mar 16, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The treatment of sexual dysfunction in human patients by an oral therapy regimen of administration of apomorphine and sildenafil is disclosed. This treatment optimizes the efficacy of each drug and substantially minimizes the undesirable side effects associated individually therewith. Apomorphine and sildenafil can be co-administered with a combination dosage unit or administered sequentially in separate dosage units, substantially prior to sexual activity. Other erectogenic agents can be administered along with apomorphine and sildenafil.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.